Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.190 AUD
−58.65 M AUD
65.80 K AUD
302.22 M
About PARADIGM BIOPHARMACEUTICALS LIMITED..
Sector
CEO
Paul John Rennie
Headquarters
Melbourne
Website
Founded
2014
ISIN
AU000000PAR5
FIGI
BBG009QNWX30
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs. The company was founded by Paul John Rennie on May 2, 2014 and is headquartered in Melbourne, Australia.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PAR is 0.460 AUD — it has increased by 35.38% in the past 24 hours. Watch PARADIGM BIOPHARMACEUTICALS LIMITED.. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange PARADIGM BIOPHARMACEUTICALS LIMITED.. stocks are traded under the ticker PAR.
PAR stock has risen by 76.00% compared to the previous week, the month change is a 114.63% rise, over the last year PARADIGM BIOPHARMACEUTICALS LIMITED.. has showed a 17.95% increase.
PAR stock is 50.00% volatile and has beta coefficient of 1.63. Track PARADIGM BIOPHARMACEUTICALS LIMITED.. stock price on the chart and check out the list of the most volatile stocks — is PARADIGM BIOPHARMACEUTICALS LIMITED.. there?
Today PARADIGM BIOPHARMACEUTICALS LIMITED.. has the market capitalization of 113.56 M, it has increased by 12.29% over the last week.
Yes, you can track PARADIGM BIOPHARMACEUTICALS LIMITED.. financials in yearly and quarterly reports right on TradingView.
PARADIGM BIOPHARMACEUTICALS LIMITED.. is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
PAR net income for the last half-year is −9.69 M AUD, while the previous report showed −48.96 M AUD of net income which accounts for 80.20% change. Track more PARADIGM BIOPHARMACEUTICALS LIMITED.. financial stats to get the full picture.
No, PAR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PARADIGM BIOPHARMACEUTICALS LIMITED.. EBITDA is −64.35 M AUD, and current EBITDA margin is −97.79 K%. See more stats in PARADIGM BIOPHARMACEUTICALS LIMITED.. financial statements.
Like other stocks, PAR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PARADIGM BIOPHARMACEUTICALS LIMITED.. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PARADIGM BIOPHARMACEUTICALS LIMITED.. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PARADIGM BIOPHARMACEUTICALS LIMITED.. stock shows the neutral signal. See more of PARADIGM BIOPHARMACEUTICALS LIMITED.. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.